menu
    • menu
    [{"orgOrder":0,"company":"Aplagon","sponsor":"Tracer","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FINLAND","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"89-Zr DFO-APAC","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aplagon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aplagon \/ Tracer","highestDevelopmentStatusID":"6","companyTruncated":"Aplagon \/ Tracer"},{"orgOrder":0,"company":"Aplagon","sponsor":"FSG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FINLAND","productType":"Radiolabeled Compound","year":"2025","type":"Financing","leadProduct":"89-Zr Megabecquerel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aplagon","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Aplagon \/ FSG","highestDevelopmentStatusID":"6","companyTruncated":"Aplagon \/ FSG"}]

    Find Clinical Drug Pipeline Developments & Deals by Aplagon

    Menu

    Aplagon

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aplagon

                            Finland arrow
                            Neuroscience
                            Not Confirmed

                            Aplagon

                            Finland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 89-Zr Megabecquerel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : FSG

                            Deal Size : $7.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Aplagon Secures EUR 7 Million for APAC Phase 2a Trials

                            Details : The financing aims to fund the clinical development of cardiovascular pipeline, which includes 89-Zr Megabecquerel, is being evaluated for chronic limb threatening ischemia.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            February 03, 2025

                            Lead Product(s) : 89-Zr Megabecquerel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : FSG

                            Deal Size : $7.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aplagon

                            Finland arrow
                            Neuroscience
                            Not Confirmed

                            Aplagon

                            Finland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 89-Zr DFO-APAC

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Tracer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteer...

                            Details : 89-Zr DFO-APAC is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arterial Occlusive Diseases.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 12, 2024

                            Lead Product(s) : 89-Zr DFO-APAC

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Tracer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth